Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.09. | AcouSort AB: AcouSort receives new order boosting Central European collaboration | 90 | GlobeNewswire (Europe) | AcouSort AB today announced it has received a third order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's novel technology for... ► Artikel lesen | |
ACOUSORT Aktie jetzt für 0€ handeln | |||||
27.08. | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 65 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen | |
28.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 186 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen | |
09.04. | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 129 | GlobeNewswire (Europe) | The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of AcouSort AB (publ) (the "Company") on 9 April 2025 in Lund.
Rights issue of sharesThe EGM resolved to approve... ► Artikel lesen | |
09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 194 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
26.03. | AcouSort AB: AcouSort's CEO answers questions about the company's rights issue and gives his view on the future | 206 | GlobeNewswire (Europe) | In connection with AcouSort's announcement of its plan to carry out a rights issue, several shareholders have contacted the company with questions regarding both the issue itself and how the management... ► Artikel lesen | |
19.03. | AcouSort AB: AcouSort in new collaboration to improve sepsis treatment | 227 | GlobeNewswire (Europe) | AcouSort's business strategy relies on early development collaborations to integrate its separation technology in partnering companies' products and systems. The most recent collaboration of this kind... ► Artikel lesen | |
03.03. | AcouSort AB: AcouSort and Bio-ReCell enter collaboration | 188 | GlobeNewswire (Europe) | AcouSort AB ("AcouSort") and Bio-ReCell Ltd ("Bio-ReCell") announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation... ► Artikel lesen | |
14.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2024 | 108 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
Fourth quarter for the GroupNet sales amounted to TSEK 1,221 (0)Result before tax amounted to... ► Artikel lesen | |
27.11.24 | AcouSort AB: AcouSort AB - Interim Report for the period July - September 2024 | 145 | GlobeNewswire (Europe) | Summary of the interim report
Significant events during the third quarterOn July 12, AcouSort announces that the Company and GenSensor will collaborate to combine AcouSort's acoustofluidics technology... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 53,58 | +1,52 % | Novonesis Hosts National Flagship Manufacturing Day Event at North America Headquarters | ||
BIOCRYST PHARMACEUTICALS | 6,286 | +1,16 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
SARTORIUS STEDIM BIOTECH | 186,70 | 0,00 % | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
ADMA BIOLOGICS | 14,390 | -1,10 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
BIOLIFE SOLUTIONS | 23,600 | 0,00 % | BioLife Solutions veräußert Kühlketten-Logistiksparte für 25,5 Mio. US-Dollar | ||
CRESCENT BIOPHARMA | 9,800 | +1,55 % | XFRA C68: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
EVOTEC | 6,786 | +1,31 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
BIONTECH | 88,90 | +1,20 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 22,960 | +1,37 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
RECURSION PHARMACEUTICALS | 5,460 | +2,92 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
GUBRA | 54,85 | -4,19 % | Pila Pharma AB: Pila Pharma Enters Into Agreement With The Cro Gubra On Preclinical Trials Of Xen-d0501 In Obesity | PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing novel oral drugs for treatment of obesity and diabetes based on TRPV1 inhibition, informs investors and others with interest... ► Artikel lesen | |
BB BIOTECH | 40,850 | +0,12 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
MODERNA | 23,790 | +3,59 % | Moderna, Inc.: Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress | mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 21,640 | +2,41 % | Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' |